A retrospective, real-world, observational study compare 6 and 12 month adherence and persistence among dulaglutide (DU) vs matched injectable semaglutide (SEMA) initiators using real-world administrative claims data from the IBM MarketScan Databases
Latest Information Update: 16 Mar 2022
At a glance
- Drugs Dulaglutide (Primary) ; Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Mar 2022 Results published in the Clinical Therapeutics
- 02 Dec 2021 New trial record